Alzheimer's Treatment: Experimental Vaccine Shows Promise

Newsweek - A new experimental Alzheimer’s disease vaccine has proven effective during recent testing in animals, prompting researchers to move toward human trials with great hope. Researchers at the University of Texas Southwestern Medical Center stated that this new vaccine showed significant delays in the effects of the degenerative brain disease after numerous animal trials. According to the Alzheimer’s Association, the disease is the sixth leading cause of death in the United States, and 5.7 million Americans are currently living with Alzheimer’s. The latter number is projected to increase to 14 million by the year 2050.

This vaccine’s methodology prompts the body to produce antibodies that reduce the buildup of two proteins called amyloid and tau, both of which are typically indicative of the degenerative brain disease’s presence in the body. This preventative technique stops the disease from spreading through the brain, potentially delaying onset by at least five (5) years.

Demonstrated by the arduous path from animal testing to human use, the requirements for proving a vaccine safe and effective are extensive. Previous Alzheimer's vaccines have fallen short of the safety standard by causing damaging side effects such as brain inflammation. However, researchers estimate that if human trials are successful, this vaccine could yield significant results for those suffering with degenerative brain disease as well as their families. Alzheimer’s disease is the leading cause of dementia, meaning that this vaccine could reduce the total number of dementia diagnoses in half. This vaccine is quickly becoming a monumental push forward in the fight against brain disease.

You can read the full article by Newsweek here.